¥ 21,413
  • 参考価格: ¥ 21,606
  • OFF: ¥ 193 (1%)
通常配送無料 詳細
通常1~4週間以内に発送します。 在庫状況について
この商品は、Amazon.co.jp が販売、発送します。 ギフトラッピングを利用できます。

お届け先住所
アドレス帳を使用するにはサインインしてください
または
-
正しい郵便番号を入力してください。
または
この商品をお持ちですか? マーケットプレイスに出品する
裏表紙を表示 表紙を表示
サンプルを聴く 再生中... 一時停止   Audible オーディオエディションのサンプルをお聴きいただいています。
この画像を表示

Translational Toxicology: Defining a New Therapeutic Discipline (Molecular and Integrative Toxicology) (英語) ハードカバー – 2016/4/7


その他(2)の形式およびエディションを表示する 他のフォーマットおよびエディションを非表示にする
Amazon 価格
新品 中古品
Kindle版
ハードカバー
¥ 21,413
¥ 18,025 ¥ 15,990
click to open popover

キャンペーンおよび追加情報

  • 本カテゴリの商品を2500円以上購入で買取金額500円UPキャンペーン対象商品です。商品出荷時に買取サービスでご利用いただけるクーポンをメールにてご案内させていただきます。 詳細はこちら (細則もこちらからご覧いただけます)
  • 【判型について】 洋書の主な判型については こちらをご確認ください。

  • 【買取サービス】 Amazonアカウントを使用して簡単お申し込み。売りたいと思った時に、宅配買取もしくは出張買取を選択してご利用いただけます。 今すぐチェック。

Kindle 端末は必要ありません。無料 Kindle アプリのいずれかをダウンロードすると、スマートフォン、タブレットPCで Kindle 本をお読みいただけます。

  • Apple
  • Android
  • Android

無料アプリを入手するには、Eメールアドレスを入力してください。


商品の説明

内容紹介

Bringing together a distinguished interdisciplinary team of contributors, this volume provides a comprehensive exploration of translational toxicology―a systematic approach to developing therapeutic interventions that can protect against, mitigate, or reverse the effects of exposures. In particular, the book addresses modes of action and biomarkers, developmental risks of exposures, and potential translational toxicology therapeutics. The result is a compelling application of developmental toxicology in a new therapeutic discipline that is destined to become part of standard medical practice.

Translational Toxicology: Defining a New Therapeutic Discipline is an essential text for regulatory authorities, scientists, and physicians who are concerned with environmental exposures, public health, nutrition, and pharmaceutical research and development. Basic science, epidemiological, and clinical investigators will also find this book a significant resource.

著者について

Claude L. Hughes, M.D., Ph.D. is Executive Director in the Therapeutic Science & Strategy Unit within Quintiles Inc. He is board-certified in Obstetrics & Gynecology and Reproductive Endocrinology and Infertility. He is a Consulting Professor in the Department of Obstetrics & Gynecology, Duke University Medical Center and an Adjunct Professor in the Department of Mathematics, North Carolina State University and in the Department of Pathology/Comparative Medicine, Wake Forest University School of Medicine.

Since joining Quintiles in 2001, Dr. Hughes has served as a Medical Advisor on clinical trials or in due diligence assessment teams that evaluated pharmaceuticals, devices or tests for several medical indications. Therapeutic areas for clinical trials and/or product evaluation have included the following: 
1) Reproductive Medicine - female sex hormone therapy, male sex hormone therapy, contraception, infertility, in vitro fertilization-embryo transfer, polycystic ovary syndrome, SERMs, overactive bladder/urinary incontinence, endometriosis, preterm labor, ovarian cancer, cervical cancer, microbicides, dysmenorrhea, gynecologic infections, female and male sexual dysfunction, erectile dysfunction, BPH/LUTS, delayed puberty in boys, primary and secondary hypogonadism in boys.
2) General Endocrinology, Metabolism and Cardiovascular Diseases – osteoporosis prevention and treatment, diabetes mellitus, thyroid hormone replacement, growth hormone therapy in children, hypertension (including use of ambulatory blood pressure monitoring - ABPM) and chronic renal disease.
3) Other Medical Conditions – GERD, opioid-induced constipation, rheumatoid arthritis, sleep disorders, migraine headaches, neuropathic pain and psoriasis. 
4) Laboratory Testing Methods - genital cytologic screening and molecular biomarker screening.
5) Drug Delivery - new systems for transdermal, buccal or vaginal administration of drugs.

Prior to joining Quintiles, Dr. Hughes held academic, research, administrative and clinical practice positions for 15 years in divisions of reproductive endocrinology & infertility in departments of obstetrics & gynecology and clinical and research centers within university-affiliated medical centers. His academic research emphasized investigating the effects of natural and man-made sex hormone-like compounds in the diet in laboratory animal and human studies. Continuing collaborative academic research is supported by a National Science Foundation grant in the Department of Mathematics at North Carolina State University (Dr. Hughes is the co-Principal Investigator).

Since April 2008, Dr. Hughes has served as a member of the Metabolic Disorders Steering Committee (MDSC) of The Biomarkers Consortium, the public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) that includes government, industry, patient advocacy groups, and other non-profit private sector organizations such as the National Institutes of Health, the Food and Drug Administration, and the Pharmaceutical Research and Manufacturers of America.


Michael D. Waters is a former government scientist with more than 35 years of experience in research and research management positions at US EPA and NIH/National Institute of Environmental Health Sciences in Research Triangle Park, NC USA.  He retired as Chief Scientist, Emeritus, from Integrated Laboratory Systems (ILS), Inc. in 2013.  He served as Assistant Director of the NIEHS National Center for Toxicogenomics from 2000 to 2007, and was responsible for a major initiative to develop the Chemical Effects in Biological Systems (CEBS) toxicogenomics knowledgebase.  CEBS is now the data repository of the US National Toxicology Program and is being utilized by the NIH and other government agencies as well as the academic, industrial, and international regulatory scientific communities for the deposition, retrieval and interpretation of toxicology and toxicogenomics data.  At NIEHS, he served on the NIH Bioinformatics and Computational Biology Roadmap Working Group, the US FDA Advisory Committee for Pharmaceutical Science, Pharmacology and Toxicology Subcommittee, the Toxicogenomics and Risk Assessment Committee of the International Programme on Chemical Safety (IPCS), the Advisory Board of the Microarray Gene Expression Data (MGED) Society and the Scientific Advisory Board of the Rat Genome Database (RGD).  For 30 years he directed research in cellular pathology, biochemistry, and genetic toxicology in various capacities at the EPA in RTP, NC. He also served EPA as an Assistant Laboratory Director with programmatic responsibility for international, waste, and multi-media research programs.  At EPA he conceived, designed, and helped to develop the EPA Gene-Tox database, now hosted by the National Library of Medicine.  He also developed the EPA/International Agency for Research on Cancer (IARC) Genetic Activity Profile (GAP) Database which formed the basis for the use of short-term tests in the evaluation of presumptive human carcinogens by the IARC.  His research interests have centered on the evaluation of chemically-induced mutations and altered molecular expression in the etiology of cancer and genetic disease. A widely-published scientist, he has edited Mutation Research-Reviews for nearly 20 years and has held adjunct professorships at both the University of North Carolina at Chapel Hill and at Duke University.  He has served as President of the Environmental Mutagen Society and the International Association of Environmental Mutagen Societies.  The databases he developed and a number of his publications are recognized as important advances that have significantly impacted the fields of genetic toxicology, carcinogenesis, toxicogenomics, and risk assessment.


登録情報

  • ハードカバー: 380ページ
  • 出版社: Humana Press; 1st ed. 2016版 (2016/4/7)
  • 言語: 英語
  • ISBN-10: 3319274473
  • ISBN-13: 978-3319274478
  • 発売日: 2016/4/7
  • 商品パッケージの寸法: 15.9 x 2.5 x 23.5 cm
  • おすすめ度: この商品の最初のレビューを書き込んでください。
  • さらに安い価格について知らせる
    この商品を出品する場合、出品者サポートを通じて更新を提案したいですか?

  • 目次を見る

カスタマーレビュー

まだカスタマーレビューはありません。
他のお客様にも意見を伝えましょう
同様の商品をご覧になりませんか? こちらのリンクで参照ください。ドレス 子供 ロング